Bibliography
- Ferrer JC, Favre C, Gomis RR, Control of glycogen deposition. FEBS Lett 2003;546:127-32
- Henry RR, Ciaraldi TP, Abrams-Carter L, Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. Biochemical and molecular mechanisms. J Clin Invest 1996;22:1231-6
- Krssak M, Brehm A, Bernroider E, Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004;53:3048-56
- Virkamaki A, Yki-Jarvinen H. Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Diabetics 1999;48:1101-7
- F. Hoffman-La Roche AG. Preparation of biaryloxymethylarenecarboxylic acids as glycogen synthase activator. US0266856; 2004
- F. Hoffman-La Roche AG. Biaryloxymethylarene carboxylic acids. WO06058648; 2006
- F. Hoffman-La Roche AG. Aniline analogs as glycogen synthase activators. US7939569; 2011
- F. Hoffman-La Roche AG. Indazolone derivatives as glycogen synthase activators. WO11057993; 2011
- F. Hoffman-La Roche AG. Indazolone derivatives as glycogen synthase activators. WO11058122; 2011
- F. Hoffman-La Roche AG. Biphenyl carboxylic acids and bioisosters as glycogen synthase activators. WO11058154; 2011
- Skaltsounis A-L, Gaboriaud-Kolar N. (WO2011057959) Indole and indazole derivatives as glycogen synthase activators: a patent evaluation. Expert Opin Ther Pat 2011;21:1925-9
- 239th American Chemical Society National Meeting and Exposition. Discovery of potent, selective and orally efficacious glycogen synthase activators as a potential treatment for type 2 diabetes. Medi-529. San Francisco; 2010
- 70th Annual Meeting and Scientific Sessions of the American Diabetes Association. A Novel approach for the treatment of type 2 diabetes (T2D): characterization of a potent, orally active, small molecule glycogen synthase activator [abstract 1389-P]. Orlando; 2010
- Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today 2009;14:1011-20
- Ritchie TJ, Macdonald SJF, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today 2011;16:164-71